Apogee Therapeutics officially completed its initial public offering and began trading its common shares on the Nasdaq Global Select Market under the ticker symbol APGE in July 2023. The clinical-stage biotechnology company successfully upsized its initial public offering to raise substantial capital, securing funding to advance its innovative pipeline of advanced biologic treatments targeting immunological and inflammatory diseases.